In The Most Recent Trial, Eli Lilly’s Obesity Drug Helped Patients Lose 25% Of Their Body Weight
In The Most Recent Trial, Eli Lilly’s Obesity Drug Helped Patients Lose 25% Of Their Body Weight According to recent studies, tirzepatide from Eli Lilly may support ongoing weight-loss initiatives. In the most recent scientific experiment conducted by the company, researchers discovered that participants who lost at least 5% of their body weight before taking the medication continued to lose a lot more weight than those who took a placebo. Over a 16-month period, individuals in the therapy group on average dropped 60 pounds, or 25% of their initial weight. The main component of Eli Lilly’s type 2 diabetes medication Mounjaro, which was given FDA approval last year, is tirzepatide. It combines GLP-1 and GIP, two hormones that are important for regulating our metabolism and appetite. In the upcoming months, the FDA is anticipated to approve tirzepatide as a treatment for obesity on the basis of extensive, randomised, and controlled clinical trials demonstrating its efficacy in assisting ...